CTOs on the Move

Mind Medicine

www.mindmed.co

 
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mindmed.co
  • One World Trade Center Suite 8500
    New York, NY USA 10007
  • Phone: 203.648.5275

Executives

Name Title Contact Details
Bradford Cross
 Chief Technology Officer Profile
Bradford Cross
 Chief Technology Officer Profile

Funding

Mind Medicine raised $24M on 02/27/2020
Mind Medicine raised $25M on 10/09/2020

Similar Companies

http://www.katumbas.com/

http://www.katumbas.com/ is a Orem, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Provivi

We are a groundbreaking science-based company creating scalable, safer insect control technology that will improve the quality of life for all humans and our world.

Waterdiam

Makindus

Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.

Arno Therapeutics, Inc.

Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors.